Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 · Annals of Oncology · 2,817 citations
https://doi.org/10.1093/annonc/mdy495
S
Solange Peters
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
929
Papers
70.4K
Citations
112
h-index
401
i10-index
Solange Peters is an academic researcher from University Hospital of Lausanne. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Immunotherapy and Biomarkers & Lung Cancer Diagnosis and Treatment. The author has an h-index of 112, co-authored 790 publications.
ORCID: 0000-0002-0412-7143Papers by this author
worksNivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
2019 · New England Journal of Medicine · 2,755 citations
https://doi.org/10.1056/nejmoa1910231
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
2021 · The Lancet · 1,154 citations
https://doi.org/10.1016/s0140-6736(20)32714-8
Brain metastases
2019 · Nature Reviews Disease Primers · 981 citations
https://doi.org/10.1038/s41572-018-0055-y
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2022 · Annals of Oncology · 966 citations
https://doi.org/10.1016/j.annonc.2022.10.001
Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
2013 · Journal of Clinical Oncology · 654 citations
https://doi.org/10.1200/jco.2012.45.6095
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat